Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Major Depressive Disorder
NCT01556971Phase 4Unknown
- Sponsor
- Capital Clinical Research Associates
- Start
- Feb 2011
- Primary completion
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in major depressive disorder (MDD), sponsored by Capital Clinical Research Associates. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01556971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01556971.